Research programme: heterocyclic hydrazone therapeutics - Vion

Drug Profile

Research programme: heterocyclic hydrazone therapeutics - Vion

Alternative Names: EPH 116; EPH 135; EPH 136; EPH 278; EPH 279; EPH 280; EPH 286; EPH 289; EPH 349; EPH 350; EPH 351; EPH 369; EPH 52

Latest Information Update: 13 Jul 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Austria Wirtschaftsservice; University of Innsbruck
  • Developer Vion Pharmaceuticals
  • Class Heterocyclic compounds; Hydrazones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 13 Jul 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 30 Apr 2007 Preclinical development is ongoing in USA
  • 26 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top